Guggenheim starts ‘pioneer’ Tempus AI with a Buy

As previously reported, Guggenheim analyst Subbu Nambi initiated coverage of Tempus AI (TEM) with a Buy rating and $74 price target Tempus is a “pioneer” in Intelligent Diagnostics that offers unique diagnostic insights via its proprietary and differentiated database, as well as selling data licenses and related services to biopharma customers, the analyst tells investors. Tempus operates in “high-growth, attractive” oncology diagnostics end-markets, adds the analyst, who expects Tempus’ unique data and one-stop shop oncology diagnostics menu to be “key competitive advantages to support future growth.”